News | August 17, 2025
Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Rivaroxaban is used to treat venous thromboembolism
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Reinforcing commitment to ethical and sustainable growth
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Subscribe To Our Newsletter & Stay Updated
